INTRODUCTION
Interferons provide a primary line of defense against virus infections by inducing genes which encode anti-viral proteins, including the 2′,5′-linked oligoadenylates (2-5A)-synthetases (1) . These synthetases require double-stranded RNA, generated by the infecting virus, to produce a series of short 2′,5′-linked oligoadenylates (2-5A) from ATP (2) . Accordingly, 2-5A has been observed in interferon-treated mammalian cells infected with encephalomyocarditis virus (EMCV), vaccinia virus, reovirus, herpes simplex and SV40 (3) . The function of 2-5A is to activate a latent endoribonuclease, the 2-5A-dependent RNase L, resulting in the rapid decay of viral and cellular single-stranded RNA (4) . The physiolgical role of the 2-5A system was investigated in RNase L-null mice which are defective for the anti-EMCV effect of interferon and show apoptotic defects in the thymus gland (5) .
RNase L has an interesting arrangement of structural and functional domains. An isolated N-terminal half, containing nine ankyrin-repeats and two P-loop motifs, binds 2-5A but lacks RNase activity. An isolated C-terminal half cleaves RNA in the absence of 2-5A (6) . Therefore, the regulatory and a catalytic functions of RNase L are present in the N-and C-terminal halves, respectively. Previous studies involving biochemical and biophysical methods demonstrated that purified, recombinant RNase L, dimerized during the 2-5A-dependent activation process (6) (7) (8) . Therefore, dimerization is intimately-linked to functional activation of the ribonuclease. However, the significance of these observation has remained obscure in the absence of in vivo evidence for the self-association of RNase L. In this regard, protein-protein interactions in cell-free systems do not necessarily reflect the situation in intact living cells.
To monitor and study RNase L dimerization in response to 2-5A, we have adapted the two-hybrid system originally developed for yeast by Fields and Song (9) . Two-hybrid systems utilize fusion proteins to detect protein-protein interactions via the activation of reporter gene expression. They are based on the observations that many eukaryotic transcriptional activators (including GAL4) consist of two physically separable modular domains; one acting as a DNA-binding domain the other as a transcriptional activation domain (10) . For instance, a mammalian two-hybrid system uses the transactivation domain of the herpes simplex virus VP16 protein and the GAL4 DNA-binding domain (11) (12) (13) . Two-hybrid assays provide sensitive methods for detecting weak or transient interactions, probably the norm in many physiological complexes. Because the assays are performed in intact mammalian cells, the proteins are likely to be properly modified and in their native conformations. Two-hybrid systems have been used to identify novel proteins (from a library of proteins) that interact with a protein of interest, test known proteins for interaction, define protein domains or specific amino acid residues required for interaction between two known proteins and identify compounds that affect these interactions (reviewed in 14).
Here we have developed a mammalian two-hybrid system in which chimeras of RNase L control the expression of a reporter gene in response to 2-5A. These findings provide the first evidence that 2-5A induces dimerization of RNase L in intact cells. This method will allow mapping of the RNase L dimerization domain and screening for RNase L activators that could function as anti-viral or anti-cancer drugs.
MATERIALS AND METHODS

Construction of plasmids
Maps of the plasmids used in the study are shown (Fig. 1 (12, 15, 16) and plasmids pG5luc and pCMV/β-gal were kindly provided by R.Patel and G.Sen. (Cleveland) (13) . To generate in frame fusion proteins of RNase L, an EcoRI site was created at the 5′-terminus of the RNase L coding sequence. A portion of the human RNase L cDNA was amplified from plasmid pZC5 (4) with an EcoRI site at the 5′-end of the cDNA with the PCR primers 5′-TGG CAT TTG AAT TCA TGG AG-3′ and 5′-GAG TTT GCC AAT CAT AGG G-3′. The PCR product was cloned into pZC5 digested with EcoRI and NcoI to give pSNL-1. Both pSNL-1 and pVP16AASV19N were digested with EcoRI and HindIII and the fragments were ligated to generate pVP16/hRL. To construct pGal/hRL, pSNL-1 was digested with EcoRI and ClaI/(blunted-ended) and ligated with pSG424 digested with EcoRI and XbaI/(blunt-ended). The human RNase L cDNA lacking 80 codons at the 3′-terminus (amino acids 1-661) was made by PCR amplification from pGEX/RNase L C∆80 (6) with the primers 5′-ATT ACG CAT CTG CTG CTG-3′ and 5′-GGC GGC CTC GAG TCA ATC ACC CAC AGT GTT CTG-3′ and the product was cloned into NcoI/ClaI-digested pSNL-1 to generate pSNL-2. The truncated RNase L cDNA was excised with EcoRI and HindIII and ligated to EcoRI-and HindIII-digested pVP16AASV19N to yield pVP16/hRL C∆80 . To generate pGal/hRL C∆80 , the truncated RNase L cDNA from EcoRI/ClaI (blunt-ended)-digested pSNL-2 was ligated to EcoRI/XbaI (blunt-ended) pSG424. To generate pGal/mRL ZB1 , the partial mouse RNase L cDNA (from plasmid pZB1) (4,17) was given an upstream SalI site by PCR amplification with the primers 5′-GGA AAA GGG ATC CGT CGA CGG ATG GAG-3′ and 5′-GCA CCA CAA GAG AGG AGA ATC TCG AGC A-3′ followed by cloning the fragment into BamHI-digested pZB1 to give pSNZB1. pSNZB1 and pSG424 were digested with SalI and ligated resulting in pGal/mRL ZB1 . All clones were confirmed by DNA sequencing.
Assay for expression of the fusion proteins in HeLa cells
To demonstrate the expression of the Gal4 binding domain fused to RNase L (Gal4BD-RNase L) and the VP16 transactivation domain fused to RNase L (VP16TA-RNase L), transient transfections were done in HeLa M cells. HeLa cells were plated to 75% confluency the day before the transfection in 10 cm Petri dishes. Cells were washed with PBS and fresh DMEM containing 10% FBS was added ∼1 h prior to transfection. Transfections of plasmid DNAs (8 µg) were done using lipofectamine PLUS transfection reagent according to the manufacturer's protocol (GIBCO-BRL). Just before the transfections, cells were washed with PBS, and then with OptiMEM. Transfections were done in the presence of OptiMEM. Cells were incubated with the DNA for 6-7 h and were then washed with PBS and incubated overnight with DMEM containing 10% FBS. Cells were split into 150 mm Petri dishes and grown an additional 24 h. Protein extracts were made in NP-40 lysis buffer (0.5% v/v NP-40, 90 mM potassium chloride, 1 mM magnesium acetate, 10 mM HEPES, pH 7.6 and 2 mM 2-mercaptoethanol) containing the protease inhibitor, leupeptin (100 µg/ml) (18) . Cell extracts, containing 150 µg of protein per sample, were denatured and electrophoresed on 10% SDS-polyacrylamide gels. Proteins were transferred to Immobilon-p membranes (Milipore) using a Trisglycine-methanol buffer. Fusion proteins, as well as endogenous RNase L, were detected on the blots using monoclonal antibody against human RNase L (22) (1:2000) for 16 h at room temperature followed by 4_C for 16 h. Actin was detected with a monoclonal antibody to a highly conserved region of actin (clone C4; Boehringer-Mannheim) (1:5000) for 1 h at room temperature (added after the incubations with the antibody against RNase L). Detection was done using anti-mouse IgG/ horseradish peroxidase (GIBCO-BRL) (1:5000) and the ECL detection system (Amersham).
2′,5′-Oligoadenylates
The p 3 A(2′p5′A) 2 was synthesized from ATP with HeLa cell 2-5A-synthetase and purified as described (18) . The pA(2′p5′A) 3 , SpA(2′p5′A) 3 and SpA(2′p5′A) 3 -anti-PKR3′-3′C [subsequently 'SpA(2′p5′A) 3 -antisense'] (19) were chemically synthesized and kindly provided by Guiying Li (Cleveland). The p 3 A2′p5′A and p 3 A(2′p5′A) 3 were generous gifts from Paul F. Torrence (Bethesda).
Transfections and assays for luciferase and β-galactosidase activities
HeLa cells were cultured in 6-well dishes to 80% confluency in Dulbecco's modified medium (DMEM) plus 10% fetal bovine serum (FBS). Plasmids (1 µg each) in 100 µl of OPTIMEM (GIBCO-BRL) were mixed with 6 µl of lipofectamine (GIBCO-BRL) in 100 µl of OPTIMEM and incubated at room temperature for 20 min. Cell culture media was aspirated, cells were washed twice and 0.8 ml of OPTIMEM was added to each well. The DNA/lipofectamine mixture was added dropwise to the cells and incubated for 6 h at 37_C. Cells were washed twice with PBS and incubated with DMEM plus 10% FBS for 15 h. Cells were then transfected with 2-5A using reagents in an MBS/mammalian transfection kit (Stratagene). A calcium phosphate precipitate of 2-5A was prepared in HEPES-buffered saline, pH 7.05, plus 125 mM of CaCl 2 . After aspirating the media, washing cells twice with PBS, and adding 1.5 ml of DMEM supplemented with either 6% MBS or 10% FBS, the precipitates were pipetted onto cells and incubated at 37_C for 90 min. The mixtures were aspirated and the monolayers were incubated with DMEM containing 10% FBS for ∼22 h. Cells were harvested by scraping in PBS, centrifuged for a few seconds in a microfuge, resuspended in 60 µl of reporter lysis buffer (Promega), incubated at room temperature for 15 min, vortexed briefly, freeze/thawed once on dry ice/37_C, centrifuged for 5 min at 10 000 g, and the supernatants were collected and assayed for luciferase activity as described (Promega). Alternatively, 2-5A were incubated with 30 mg/ml of DEAE-dextran at room temperature for 10-15 min (20) . The mixtures were diluted in OPTIMEM in 100 µl, and added to cells from which media was removed. OPTIMEM, 0.9 ml, was immediately added and cells were incubated for 90 min at 37_C. Cells were incubated for 22 h with fresh media and extracts were prepared as described above. To determine the transfection efficiency, β-galactosidase activity was measured by determining the optical density at 420 nm after incubation at 37_C of cell extracts with o-nitrophenyl-β-D-galactopyranoside (Sigma) (20) . Results are expressed as the ratio of the luciferase activity/β-galactosidase activity, normalized so that the ratio in the control cells equals 1.0. Control cells were transfected with pGal/hRL, pVP16/hRL, pGal5/luc and pCMV/β-gal in the absence of 2-5A.
RESULTS AND DISCUSSION
Design of plasmids for the two-hybrid system and expression in HeLa cells
To establish whether RNase L forms dimers in intact cells, and to create a convenient, high-throughput method for measuring a biological response to 2-5A, hybrids of RNase L were generated (Figs 1 and 2) . Plasmids pGAL/hRL and pVP16/hRL encode the yeast GAL4 DNA-binding domain and the HSV VP16 transactivation domain, respectively, fused to the N-terminus of human RNase L. N-terminal fusions of RNase L were made, instead of C-terminal fusions, because glutathione-S-transferase fusions to the N-termini of RNase L are fully functional (6, 21) . Previously, we implicated a C-terminal region of RNase L as being important for dimer formation in cell-free systems (6) . Therefore, to determine if the C-terminal tail of RNase L is required for dimer formation in intact cells, hybrid proteins lacking 80 C-terminal amino acids of RNase L were constructed (see plasmids pGal/hRL C∆80 and pVP16/hRL C∆80 , Fig. 1) . To obtain mechanistic information about a dominant negative mutant of the murine RNase L, lacking a C-terminal tail, RNase L ZB1 was fused to the VP16 transactivation domain (Fig. 1 , plasmid pVP16/mRL ZB1 ) (17) . The reporter plasmid, pGal5/luc, contains five Gal4 binding sites upstream of a minimal E1B promoter and the luciferase coding sequence. The plasmid, pCMV/β-gal, containing a CMV promoter linked to β-galactosidase cDNA, was used to control for transfection efficiency. Dimerization of RNase L was indirectly measured by the luciferase activity normalized for β-galactosidase activity.
To demonstrate that the fusion protein could be expressed in cells, plasmids pGAL/hRL and pVP16/hRL were individually transfected into HeLa cells (Fig. 2) . Western blots prepared from extracts of the transfected cells were probed with monoclonal antibodies against human RNase L and actin. In the control, non-transfected cells, the endogenous RNase L (83.5 kDa) and actin isoforms (42 kDa) were clearly seen (lane 1). In cells transfected with pGAL/hRL, the GAL4BD-RNase L fusion protein was also observed near its expected position (the GAL4 BD is 17 kDa) (lane 2). In addition, there was an apparent breakdown product of the GAL4BD-RNase L just below the intact fusion protein (second band from top in lane 2). Cells transfected with pVP16/hRL produced the VP16TA-RNase L fusion protein which migrated to a position relative to the molecular weight markers which is slightly larger than its actual size of 92 kDa (lane 3).
A comparison of the relative efficiencies of different methods for introducing 2-5A into HeLa cells
To determine if the RNase L fusion proteins could interact in cells, a mixture of plasmids pGal/hRL, pVP16/hRL, pGal5/luc and pCMV/β-gal was transfected into HeLa cells using lipofectamine. After 15 h, the cells were transfected with 1 µM of p 3 A(2′p5′A) 2 by calcium phosphate co-precipitation in the presence of FBS. Luciferase and β-galactosidase activities were determined after an additional 22 h of cell culture. A 2.7-fold increase in the ratio of luciferase to β-galactosidase demonstrated that dimerization of the hybrid proteins occurred in the cells (Fig. 3) . However, calcium-phosphate co-precipitation in media containing FBS caused the death of a substantial proportion of the cells when used in conjunction with lipofectamine. DEAE-dextran was even less effective than the calcium-phosphate/FBS technique, resulting in a 2.2-fold relative increase in luciferase activity. The MBS method, which involves calcium-phosphate co-precipitation in the presence of a modified bovine serum, was the least harmful to the cells of the three methods, and resulted the highest ratio of luciferase to β-galactosidase activity, a 3.7 " 0.6-fold increase (Fig. 3) . Therefore, in all subsequent experiments the 2-5A were introduced into the cells by the MBS method.
Formation of RNase L dimers in human cells requires the presence of a 2-5A
To determine the effect of 2-5A on RNase L dimerization, cells were transfected with the mixture of pGal/hRL, pVP16/hRL, pGal5/luc and pCMV/β-gal, followed after 15 h with either a mock transfection, or transfections with different amounts of p 3 A(2′p5′A) 2 (Fig. 4) . In the absence of p 3 A(2′p5′A) 2 there was only a very low basal activity of luciferase activity, suggesting the RNase L does not dimerize unless 2-5A is present. In contrast, a dose-dependent increase of luciferase/β-galactosidase was observed in cells transfected with p 3 A(2′p5′A) 2 . RNase L dimerization was clearly detected at ≤200 nM of p 3 A(2′p5′A) 2 . The maximal relative increase of luciferase activity, 4.0 " 0.56-fold, was obtained with 2 µM of p 3 A(2′p5′A) 2 . These findings demonstrate that 2-5A induces dimers of RNase L in intact human cells. 
Only functionally active forms of 2-5A cause RNase L dimers to form in human cells
Activation of RNase L requires 2-5A that contain a minimum of three adenylyl residues (22, and references therein). To determine if the dimerization of RNase L was specific for functional forms of 2-5A, we compared a panel of 2-5A in the two-hybrid system (Fig. 5) . The dimer, p 3 A2′p5′A, failed to induce luciferase activity. Similarly, in a previous study we showed that p 3 A2′p5′A fails to cause RNase L to dimerize in vitro (7) . In contrast, p 3 A(2′p5′A) 2 and p 3 A(2′p5′A) 3 resulted in an ∼4-fold increase in luciferase/β-galactosidase activity, while the monophosphate, pA(2′p5′A) 3 , and the thiophosphate, SpA(2′p5′A) 3, caused an ∼2-fold increase. All four of these compounds, p 3 A(2′p5′A) 2 , p 3 A(2′p5′A) 3 , pA(2′p5′A) 3 and SpA(2′p5′A) 3 activate RNase L in vitro to a similar extent (22, 23) . The reduced activity in the two-hybrid system of pA(2′p5′A) 3 compared to 5′-triphosphorylated 2-5A may be due to less efficient uptake due to a less negative charge and a loss of the critical α-phosphoryl group by cellular phosphatases. On the other hand, the lower activity of SpA(2′p5′A) 3 , which is resistant to phosphatase, may be due only to less efficient uptake (23) . In addition, a 2-5A antisense chimera containing SpA(2′p5′A) 3 linked to antisense DNA, which can activate RNase L but at reduced levels compared to 2-5A per se, produced a 2.3-fold increase (24) .
Mapping the dimerization domain of RNase L by the two-hybrid system
Previously, we showed with purified recombinant GST-fusion proteins that the C-terminal tail of RNase L is essential for ribonuclease activity and dimer formation, but not for 2-5A binding activity (6) . To determine if the C-terminal tail of RNase L is required for dimer formation in cells, truncated hybrid proteins were expressed (Fig. 6) . Expression of both full-length hybrid proteins followed by transfection with p 3 A(2′p5′A) 3 , resulted in a 4.8 " 0.54-fold increase in luciferase/β-galactosidase activity. In contrast, co-expression of hybrid proteins lacking 80 C-terminal amino acids of RNase L, encoded in pVP16/hRL-C∆80 and pGal/hRL C∆80 , showed little or no effect in the presence of p 3 A(2′p5′A) 3 . The combination of pVP16/hRL C∆80 and pGal/ hRL produced only an ∼1.6 " 0.9-fold increase in luciferase/β-galactosidase activity. Interestingly, the reverse combination, pVP16/hRL and pGal/hRL C∆80 , gave 3.0 " 1.1-fold increase. Therefore, the ability of truncated RNase L to heterodimerize with full-length RNase L depends in part on the type of fusion proteins that are constructed. However, perhaps as a reflection of species differences, a murine RNase L mutant lacking a C-terminal tail, encoded in pGal/mRL ZB1 , did not interact with the VP16 transactivation domain fused to human RNase L (Fig. 6) . It is interesting that murine RNase L ZB1 can nevertheless function as a dominant negative mutant in both murine and human cells (17; A.Maran, J.Paranjape and R.H.S., unpublished). Because murine RNase L ZB1 has full 2-5A binding activity, it is likely that, at least in human cells, its mode of action involves sequestering of 2-5A. In addition, there was little or no increase in the ratio of luciferase to β-galactosidase activity when pVP16/hRL and pSG424 (encoding the GAL4 DNA binding domain) or when pGal/hRL and pVP16AASV19N (encoding the VP16 transactivation domain) were introduced into the cells followed by transfection with p 3 A(2′p5′A) 3 (Fig. 6 ). These findings show that the C-terminal tail of RNase L is important for the dimerization activity in cells. However, the C-terminus may or may not contain the dimerization domain because the C-terminal deletion may cause a change in the remaining part of the RNase L protein structure.
The two hybrid system is a method for monitoring RNase L dimerization in intact cells
The 2-5A pathway provides opportunities for the development of therapeutic agents because RNase L is present in most mammalian cell types and can be activated by a small molecule, 2-5A. Furthermore, because RNase L activation is implicated in the anti-viral and anti-cellular activities of interferons, novel activators of RNase L could have anti-viral or anti-cancer activities (5, 17) . The two-hybrid system is thus a convenient, high-throughput method for screening potential RNase L activators. The assay can also be used to monitor uptake of RNase L activators (Fig. 5) and it might detect the natural occurrence of 2-5A in intact cells under different physiological conditions, such as following interferontreatment and virus-infection. It will also be possible to generate a map of the RNase L interaction domains by cloning additional mutant forms of RNase L in the two-hybrid system vectors (Fig. 6) . Finally, the ability of RNase L to dimerize in response to a small molecule provides a novel method for the control of gene expression in vivo. This method is the second example of a two-hybrid system that depends on a small molecule for the interaction of the hybrid proteins. In the first case, dimerization of FKBP12 and a FRAP fragment was mediated by rapamycin thus controlling transcription in vivo (25) . In the case of RNase L, it is unknown if the 2-5A unmask a protein-protein interaction domain which leads to dimer formation or if 2-5A bridges are formed between RNase L monomers. However, the observation that one molecule of 2-5A binds to each monomeric RNase L molecule favors the former hypothesis (8) .
Because 2-5A can both activate and dimerize RNase L, the extent of luciferase activity is limited by RNA degradation. Inhibitory effects of 2-5A transfections on protein and RNA synthesis are transient as a result of the rapid decay of 2-5A in cells (26) . It is apparent from our results that at least some of luciferase mRNA escapes to the cytoplasm and is translated into functional protein. However, as a future development of the method, it would be useful to disable the RNase domain by mutation without affecting the dimerization activity. Alternatively, perhaps a small molecule can be found or chemically-synthesized which can enter cells and dimerize RNase L without causing its catalytic activation. Hence, this assay will provide a convenient method for screening RNase L activators and in the testing and design of small molecule modulators of RNase L.
